Patients in England to get the latest drugs more quickly

Published: 29-Aug-2012

Innovation scorecard scheme aims to create a level playing field for treatments


The NHS will have to comply with guidance on new drugs and treatments from the National Institute for Health and Clinical Excellence (NICE), or explain to patients in England why there is a delay, under a new scheme announced this week.

The scheme, to be introduced by autumn, aims to create a level playing field for treatments. Currently some NHS Trusts delay offering new drugs as recommended by NICE, while others introduce them as soon as they are approved.

Under an ‘innovation scorecard’ scheme ‘the NHS will have no excuse not to provide the latest NICE-approved drugs and treatments’, the department of health said.

Health Minister Paul Burstow said: ‘Patients have a right to drugs and treatments that have been approved by NICE. This new regime will be a catalyst for change – we are determined to eradicate variation and drive up standards for everyone.’

NHS organisations will be automatically added onto lists of what drugs are available in local areas, which will be published for all to see.

The department of health says NHS organisations receive funding for each new NICE appraisal, so financial worries should not be a barrier to the uptake of innovative new treatments.

‘This new regime will ensure rapid and consistent adoption of NICE-approved drugs and treatments throughout the NHS,’ the department of health said.

See more

You may also like

Regulatory

NICE recommends Lilly’s mirikizumab for the treatment of Ulcerative Colitis

Read more
Eli Lilly has received the "go ahead" from NICE, the organisation that has recommended its mirikizumab for the treatment of adults with moderately to severely active Ulcerative Colitis

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

NICE recommends Lilly’s mirikizumab for the treatment of Ulcerative Colitis

Eli Lilly has received the "go ahead" from NICE, the organisation that has recommended its mirikizumab for the treatment of adults with moderately to severely active Ulcerative Colitis
Infection Control

Opinion: Chasing a fast-moving target

The market for new antibiotics is forecast to be huge, so why are pharma companies showing so little interest in their development?
Medical Devices

Syensqo introduces medical-grade Amodel PPA for single-use, high-temperature medical devices

A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies
Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Subscribe now